Alpha Healthcare Acquisition Corp. III (ALPA): history, ownership, mission, how it works & makes money

From its July 2021 formation as a healthcare-focused SPAC to a transformative deal that closed on July 14, 2023, Alpha Healthcare Acquisition Corp. III reshaped itself into Carmell Therapeutics Corporation through a business combination that listed the combined company on Nasdaq under CTCX (and warrants CTCXW), positioning a regenerative-medicine platform with an FDA-cleared Phase 2 trial and a leadership team led by founder-turned Executive Chairman Rajiv Shukla and CEO Randy Hubbell; backed by an initial IPO trust of $150 million, the merger conveyed an initial equity package of $65 million (including $8 million cash and $57 million stock) plus up to $75 million in milestone equity, while Carmell reported approximately $50 million in unaudited trailing twelve-month net revenue as of March 31, 2023, invested over $10 million in R&D in 2023, and markets its off-the-shelf allogeneic plasma-based biomaterials-targeting indications from open tibia fractures to spinal fusion-within a regenerative medicine space projected at roughly $1 trillion by 2025, with warrants exercisable at $11.50 per share and strategic contracts (including a national GPO pricing agreement) that underpin commercialization and milestone-driven upside.

Alpha Healthcare Acquisition Corp. III (ALPA): Intro

• Founder and leadership: Rajiv Shukla (founder) became Executive Chairman; Randy Hubbell became Chief Executive Officer.
• Strategic focus: accelerate development of plasma‑based biomaterials for soft tissue repair and orthopedic applications.
• Lifecycle: SPAC formation → target identification → definitive agreement (Jan 2023) → closing and Nasdaq listing (Jul 2023).

• Mission: Translate Carmell's regenerative medicine platform into commercial products for soft tissue repair and orthopedics.
• Strategic rationale: Use public-market capital and SPAC structure to accelerate clinical programs and scale manufacturing/partnerships.

• R&D and clinical development: advance Phase 2 programs and move toward later‑stage trials and regulatory interactions.
• Platform commercialization: develop plasma‑derived biomaterials applicable to surgical repair, wound care, and orthopedics.
• Partnerships and licensing: collaborate with device makers, healthcare systems, and distribution partners to access clinical channels.

• Product sales: commercialize regenerative biomaterial products for soft tissue and orthopedic indications.
• Licensing and partnerships: upfront payments, milestones, and royalties from strategic collaborations.
• Service and manufacturing revenue: contract manufacturing or supply agreements leveraging proprietary plasma processing.
• Milestone-based funding: non-dilutive or structured payments tied to clinical and regulatory achievements.

• SPAC route: used ALPA's public vehicle to access capital markets and provide liquidity to private biotech investors.
• Post-merger public listing: provides trading liquidity under CTCX/CTCXW and public reporting obligations to support fundraising and M&A activity.
• Leadership continuity: founder-led board (Rajiv Shukla) plus experienced biotech executive management to execute commercialization and clinical strategy.

Alpha Healthcare Acquisition Corp. III (ALPA): History

• IPO proceeds placed in trust: ~$150 million
• Merger closing date (combined entity public ticker): CTCX (Nasdaq) - as of March 31, 2025
• Merger consideration at closing: $65 million initial equity value (comprised of $8M cash + $57M in CTCX stock)
• Contingent milestone equity: up to $75 million tied to revenue/business milestones

• Public shareholders: former ALPA investors and new public investors holding combined CTCX equity.
• Carmell shareholders: received $65M in initial equity value at closing (mix of cash and CTCX stock) and are eligible for up to $75M in milestone equity payments.
• Warrants: part of the capital structure, exercisable at $11.50 per share, creating potential future dilution and capital if exercised.

• SPAC model: ALPA raised capital ($150M) held in trust until a business combination; sponsors and PIPE/backers participate in equity at closing.
• Merger economics: Carmell received upfront cash and stock ($65M total initial equity), aligning founders and legacy shareholders with public investors.
• Warrants & exercise: Warrants exercisable at $11.50 provide potential cash infusion if exercised, increasing cash on the balance sheet but diluting shareholders.
• Milestone payments: Up to $75M in milestone equity aligns future payouts with revenue and operational milestones, deferring some consideration until targets are met.
• Revenue generation (post-merger): Through commercialization of therapeutic products, licensing, partnerships, and milestone-driven equity issuance tied to revenue thresholds.

Alpha Healthcare Acquisition Corp. III (ALPA): Ownership Structure

• Carmell Therapeutics is dedicated to advancing regenerative medicine by developing allogeneic plasma-based biomaterials designed to accelerate healing and reduce infection rates in bone and soft-tissue injuries.
• The mission emphasizes off-the-shelf, ready-to-use products that eliminate the need for patient-derived materials, reducing procedural complexity and lowering per-case costs.
• Core values include integrity, innovation, excellence, collaboration, and social responsibility, guiding clinical development, manufacturing practices, and commercial strategy.
• The company commits to ethical standards, transparency, and accountability in all business practices to maintain stakeholder trust.
• Carmell invested over $10,000,000 in 2023 toward research and development to accelerate technology development in regenerative medicine.
• Social responsibility efforts include free health-screening programs in underserved communities and sustainability initiatives to reduce environmental footprint.

• Technology: Allogeneic plasma-derived biomaterials manufactured as off-the-shelf products for surgical and wound-care use.
• Clinical pathway: Preclinical and clinical programs target faster tissue repair and lower infection rates versus conventional grafts and biologics.
• Manufacturing & distribution: Scalable production of standardized units intended for hospital systems, outpatient surgical centers, and trauma care facilities.
• Regulatory & quality: Development strategy aligned with applicable regulatory pathways for biologics/medical devices, with an emphasis on sterility, consistency, and lot traceability.

• Product sales: Commercial pricing per unit for off-the-shelf biomaterials sold into surgical and wound-care channels.
• Reimbursement strategy: Targeting CPT/DRG-aligned reimbursement and hospital formulary adoption to drive uptake and recurring revenue.
• Partnerships & licensing: Co-development and licensing agreements for specific indications or geographies.
• Acquisition value-creation: For ALPA as sponsor, value accrues through equity appreciation post-business combination, milestone payments, and potential dividends from profitable operations.

Alpha Healthcare Acquisition Corp. III (ALPA): Mission and Values

• Core mission: accelerate safe, cost-effective regenerative therapies that reduce healing time and infection risk while lowering procedural complexity for providers.
• Value emphasis: collaboration with clinicians, evidence-driven development, scalable manufacturing, and patient accessibility.

• Product platform: allogeneic plasma-based biomaterials designed as off-the-shelf, ready-to-use implants and topical applications that do not require autologous (patient-derived) material.
• Development stages: pre-clinical characterization followed by phased clinical programs (Phase 1/2 and Phase 2 as relevant to specific indications).
• Manufacturing approach: centralized, scalable aseptic manufacturing to produce consistent lots for multi-site clinical use and eventual commercialization.
• Clinical collaborations: partnerships with orthopedic, dental, wound-care, and dermatology providers to run trials and gather real-world evidence.

• FDA engagement: Carmell has received FDA clearance to initiate a Phase 2 clinical trial studying accelerated healing and reduced infections in open tibia fractures treated with intramedullary rodding.
• Clinical focus metrics: endpoints include time-to-union, infection rate reduction, re-operation rates, and functional outcomes-typical Phase 2 powered endpoints to demonstrate biological effect and safety.

• Product sales: one-time procedural implants (e.g., bone graft substitutes) and repeat-use topical products (e.g., wound-care matrices, aesthetic formulations).
• Channel strategy: direct hospital/health system sales, distributor partnerships for dental and aesthetic markets, and clinic-level consumable sales for wound care and dermatology.
• Reimbursement approach: pursue coding and payor engagement for surgical adjuncts and wound-care products; leverage clinical trial data to support payer coverage and favorable hospital formulary placement.
• Cost structure advantages: allogeneic, off-the-shelf format reduces OR time and eliminates need for autologous harvesting, potentially lowering procedural costs and improving hospital adoption economics.

• Clinical partners: orthopedic trauma centers, dental surgeons, wound-care specialists, and dermatology clinics engaged for trial sites and protocol development.
• Investor alignment: strategic investors and sponsors focused on accelerating pivotal trials and commercial readiness.
• Health-economic focus: collection of cost-effectiveness and real-world outcome data to support market access and adoption.

Alpha Healthcare Acquisition Corp. III (ALPA) How It Works

• Founded as a healthcare-focused blank-check company, Alpha Healthcare Acquisition Corp. III (ALPA) completed its initial public offering to fund mergers and acquisitions in the healthcare sector.
• Ownership structure: public SPAC shareholders, sponsor management team, and PIPE investors formed at IPO and through subsequent financing rounds.
• IPO proceeds raised approximately $150 million, providing capital to pursue target acquisitions and support post-merger operations.

• Mission: to acquire and scale innovative healthcare companies that deliver measurable clinical and economic value to providers and patients - see the company's stated purpose: Mission Statement, Vision, & Core Values (2026) of Alpha Healthcare Acquisition Corp. III
• Core focus areas include regenerative medicine, medical devices, hospital-supplied therapeutics, and other healthcare products that can achieve rapid commercial traction.

• Acquisition vehicle: raises capital via SPAC IPO and PIPEs, identifies a target company, completes a business combination to take the target public or provide growth capital.
• Post-combination operating strategy: scale commercialization, leverage distribution relationships, and optimize unit economics through centralized services and GPO contracts.
• Capital deployment: uses IPO proceeds, sponsor equity, and follow-on financing to fund M&A, product development, and commercialization.

• Product sales: generates revenue through the development and commercialization of off-the-shelf allogeneic plasma-based biomaterials and other healthcare products sold to hospitals and providers.
• Commercial traction: achieved approximately $50.0 million in unaudited trailing twelve-month net revenue as of March 31, 2023, primarily from product sales.
• Distribution and contracting: became a preferred vendor via a national pricing contract with one of the top three largest group purchasing organizations, covering over 1,500 U.S. hospitals, increasing addressable market access and negotiated pricing.
• Revenue streams: direct sales to healthcare providers, recurring consumable sales, and potential milestone payments from strategic partnerships and acquisition-related earnouts.
• Cost advantages: off-the-shelf, ready-to-use product design reduces procedural complexity and the need for patient-derived materials, enabling lower per-case costs and faster adoption by providers.

• Direct sales force targeting hospitals, surgical centers, and specialty clinics.
• National GPO agreements to accelerate procurement and preferred placement on hospital formularies.
• Strategic OEM, distribution, and partnership arrangements that can include milestone and royalty components.

• Off-the-shelf products reduce OR time and supply complexity, improving throughput and lowering total procedural cost for providers.
• Recurring consumables and high unit margins on proprietary biomaterials support predictable revenue and attractive lifetime value per account.
• GPO-negotiated pricing can create volume-driven revenue stability while still permitting favorable margins through scale.

Alpha Healthcare Acquisition Corp. III (ALPA): How It Makes Money

• Primary revenue-generating route: completing a de-SPAC merger that converts ALPA's cash-in-trust into pro forma equity in an operating healthcare company that generates operating revenue (biotech, telemedicine, healthcare IT, regenerative medicine).
• Secondary revenue and value drivers: sponsor promote (typically 20% of post-deal equity), warrants and PIPE placements, advisory fees, and potential continued sponsor ownership]
• Value creation levers: selecting targets in high-growth healthcare niches, structuring PIPE financings, and strategic partnerships that accelerate commercial adoption.

• Target segments: biotechnology (biologics, allogeneic biomaterials), telemedicine platforms, healthcare IT (SaaS, clinical decision support), and value-based care providers.
• Strategic partnerships supporting deal flow and commercialization: Healthcare Innovation Partners, Global Health Ventures, and similar healthcare investing/advisory groups.
• Operational focus post-merger: R&D acceleration, regulatory pathway execution, and commercial rollout to convert pipeline assets into recurring revenue.

• Deal sourcing depth: ALPA's relationships with healthcare investors and operators provide access to proprietary targets across biotech, telemedicine and healthcare IT.
• Innovation and R&D emphasis: post-merger companies often prioritize R&D spend to advance clinical programs and product pipelines-key to capturing regenerative medicine market share.
• ESG & sustainability positioning: commitment to social responsibility can increase appeal to institutional investors and strategic partners.